Entropy Technologies LP Buys 598 Shares of Enovis Co. (NYSE:ENOV)

Entropy Technologies LP boosted its stake in Enovis Co. (NYSE:ENOV) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,305 shares of the company’s stock after acquiring an additional 598 shares during the period. Entropy Technologies LP’s holdings in Enovis were worth $321,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Enovis during the 3rd quarter worth approximately $55,000. FMR LLC boosted its holdings in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP bought a new position in shares of Enovis during the 3rd quarter worth approximately $206,000. 98.45% of the stock is currently owned by institutional investors.

Enovis Price Performance

Shares of NYSE:ENOV opened at $43.70 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $65.03. The stock’s 50 day moving average is $45.53 and its 200-day moving average is $44.43. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -19.96 and a beta of 1.94.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.83.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.